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Abstract: This paper considers the shape of bioethics governance in Europe, noting the 
interplay between the institutions and laws of the Union and those of the Council of Europe. 
It reviews the structures of UK bioethics governance and identifies weaknesses that Brexit 
provides an opportunity to address. It notes the ambiguous relationship of UK bioethicists 
with European institutions and discusses the importance of soft power. It explores what the 
UK should do to maintain its influence. It advocates, first, improved co-ordination of 
governance organisations within the UK. Second, a more strategic approach to ‘soft power’ 
and UK involvement with international organisations, both within the European region and 
more widely. Finally, it proposes that the UK become a signatory to the Oviedo Convention 
in order to consolidate its connections with European values. These steps are suggested as 
mitigation for the loss of influence that Brexit might otherwise bring. 
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Introduction 
 
In her letter to President Tusk notifying the Union that the UK was triggering Article 50, the 
Prime Minister wrote of  
 
… shared European values. Perhaps now more than ever, the world needs the liberal, 
democratic values of Europe. We want to play our part to ensure that Europe remains 
strong and prosperous and able to lead in the world, projecting its values and 
defending itself from security threats.
1
 
 
This paper considers what form that commitment might take in the governance of bioethical 
issues. By bioethics governance, I mean the practices through which societies mediate 
controversies, reach policy conclusions, and regulate behaviour to implement and incentivise 
adherence to such policies.
2
 These practices have emerged despite continuing controversy 
about what constitutes a bioethical issue. Over time, the original use of the term in relation to 
what is more now commonly considered environmental ethics,
3
 and also the sense of 
continuity between medical, business and military ethics,
4
 has been supplanted by a dominant 
usage in relation to health technologies.
5
  
 
The Council of Europe set out to draw up a convention on ‘bioethics’, but described it 
formally as concerning ‘Human Rights and ‘Biomedicine’ and was driven (according to the 
preamble) by concern about the risks of ‘misuse of biology and medicine’. This instrument, 
known as the Oviedo Convention, is discussed further below. The main point for this stage in 
the argument is that it proceeds from the assumption that the defining normative structure 
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derives from human rights rather than a separate discipline of bioethics. Thus, it was not, and 
is not, necessary to provide a precise definition but merely to indicate the scope of the 
enterprise that is being governed.
6
 The term bioethics is used deliberately loosely in global 
governance to encompass, in the terms of the Universal Declaration on Bioethics and Human 
Rights, ‘ethical issues related to medicine, life sciences and associated technologies as 
applied to human beings, taking into account their social, legal and environmental 
dimensions’.
7
 Following the usage of the drafters of the Universal Declaration, this paper will 
refer generically to ‘bioethics issues’ because that term ‘facilitates reference to the questions 
relevant within the scope of the declaration’,
8
 avoids the distractions of debates about the best 
meaning of the term bioethics in academic discourse,
9
 and enables the focus of the paper to 
remain on governance matters.  
 
The practice of bioethics is a complex ecology, but it has taken some shape in the form of 
governance institutions. Article 19 of the Universal Declaration sets out an expectation that 
states establish committees to address research approvals, clinical ethics, develop policy, and 
foster public debate. Marcus Duwell has offered a tripartite classification of institutional 
functions. First, there are institutions concerned with ethical reflection (including, but not 
limited to national ethics committees). Second, there are bodies providing assurance that 
ethical standards are met, including ‘gatekeeping’ committees, such as research ethics 
committees without whose permission studies cannot proceed (and in the UK statutory 
licensing bodies such as the Human Fertilisation and Embryology Authority (HFEA) and the 
Human Tissue Authority). Third, decision support for those grappling with challenging 
ethical problems to provide a sounding board or source of expert advice.
10
 The United 
Nations Educational, Scientific and Cultural Organisation (UNESCO) engages in capacity 
building,
11
 an exercise which has demonstrated the diversity of roles that national bioethics 
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committees play,
12
 as well as establishing international standards.
13
 There is this no simple 
blueprint for bioethics governance but it is a well- established area of activity. 
 
The UK has disparate arrangements in place for these governance activities, and it will be 
argued that Brexit provides an opportunity and also an incentive to review their coherence. 
However, it would be too strong a claim that reform is required by Brexit as in many ways, 
the practice of bioethics in the UK has maintained a position that is on the ‘edge’ of Europe. 
In terms of substantive concerns, UK bioethics sits somewhere between European value-
based bioethics (promoting autonomy, dignity, integrity, and vulnerability)
14
 and North 
American principlism (organised around autonomy, beneficence, non-maleficence and 
justice).
15
 While it shares the European commitment to solidarity in contrast to the 
individualism of the dominant US model, as Schotsmans has shown, UK bioethics remains 
resistant to the conceptualisation of human dignity that he characterises as ‘one of the most 
foundational European concepts’ in favour of a principle of autonomy that draws strongly 
from the version developed in North American principlism.
16
 This idea of autonomy does 
not, however, trump the enduring importance in the UK of trustworthy institutions.
17
 Nor has 
it displaced the historical pattern in which those disciplines and institutions that in the USA 
found themselves in conflict (medicine, law, theology),
18
 have acted collaboratively in 
Britain.
19
 So, while some British bioethicists think they have escaped ‘American capture’,
20
 
other commentators think that Britain is aligned with the USA against the European 
approach.
21
 
 
In terms of the institutionalisation of bioethics governance, it can also be said that the 
relationship with European practices in ambiguous. The UK has established regulatory 
structures that have adapted to EU expectations but they were not driven by them. Thus, the 
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Human Fertilisation and Embryology Acts of 1990 and 2008 emerged from domestic 
reflection on the acceptability of advances in human reproduction and only subsequently 
incorporated European law on quality and safety. A similar point can be made about 
European human rights law; that it influences but does not determine the course of UK 
bioethics. The UK Supreme Court has established that the fact that bioethical issues are 
within the margin of appreciation from the perspective of the European Court of Human 
Rights does not preclude the domestic courts employing human rights arguments drawn from 
the Convention in order to explore the authority of Parliament on bioethics matters.
22
 This 
suggests that litigation may be increasing in importance as a mechanism for progressing 
bioethical governance,
23
 something that has largely been denied and hidden until recently.
24
 
The UK has thus retained a distinct and essentially pragmatic approach. While the Nuffield 
Council on Bioethics is widely respected in the international bioethics community, the 
European pattern of overarching national ethics committees has been resisted in favour of a 
combination of non-governmental bodies and sector-specific regulators.  
 
This distributed regulatory approach could be considered a strength in its development of 
sector expertise, but it also exposes weaknesses that arise from the lack of a coherent 
foundation. The Government has stressed how important science is to the post-Brexit 
economy, and draws attention to the role of regulation in its hospitability. The Life Sciences 
Industrial Strategy pitches the UK’s ‘offer’ to the wider world partly in terms of ‘a more 
science friendly regulatory regime than that which is applied in other European countries’.
25
 
Science Minister, Sam Gyimah has proclaimed ‘Britain's new unique selling point (USP): the 
go-to place for science and innovation’ and explained that, amongst other features, the UK 
has the advantage of having  
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‘a long track record of setting world-class regulations, standards and ethical norms. If 
we can be take the lead on setting these standards, regulation and ethics, we have the 
chance to take a global lead - and to realise our vision of being a global platform.’
26
 
 
When it comes to explaining what the UK stands for in the area of bioethics, however, the ad 
hoc nature of its bioethics governance makes it hard to show how it intends to position itself 
as a world leader. If the promotion of science is not to constitute a ‘race to the bottom’ in 
terms of bioethics, such that friendliness to science means lowering ethical standards, then 
the robustness of regulation needs to be demonstrated.  
 
Thus, while Brexit does not formally require change in the area of bioethics governance, it 
does give rise to a need for greater clarity. It provides an opportunity to revisit its institutional 
architecture in order to promote better governance. This paper proposes that steps are taken to 
make the UK’s solidarity with the European tradition of bioethics more explicit, that a more 
strategic approach is taken to ensure the continuation of UK influence on the institutions that 
shape bioethical norms globally, and that there should be a more co-ordinated approach to the 
governance of bioethics within the UK itself.  
 
Bioethics and Europe 
Europe has a long history of activity in bioethics governance. France was the first European 
state to establish as national bioethics committee in 1983, but this has now become the norm. 
European institutions have played a significant role in shaping and facilitating such 
initiatives.
27
 For the European Union, the Commission established its first advisory group in 
1991, currently constituted as the European Group on Ethics in Science and New 
Technologies.
28
 Brexit does not necessarily threaten UK influence here as members are 
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appointed on a personal basis and can come from outside the EU. However, the basis for the 
work is the treaties of the European Union.
29
 Brexit thus threatens to divorce UK Bioethics 
from this activity even if individual bioethicists might remain involved. The European 
Commission also supports a European National Ethics Committee Forum,
30
 which brings 
together the Committees from the EU member states, with others sometimes attending. There 
is also a broader ‘International Dialogue on Bioethics’ that goes beyond the EU.
31
 Brexit will 
shift UK involvement from that of a European member to an international partner. Finally, it 
should be noted that the Council of Europe has also established machinery for bioethical 
reflection, with continuing interest from the Parliamentary Assembly, particularly through the 
standing Committee on Bioethics (DH-BIO).
32
 Brexit will not affect membership of this body 
as it does not entail withdrawal from the Council of Europe, only the European Union. 
However, an express task of DH-BIO is to ‘co-operate with the European Union and relevant 
intergovernmental bodies, in particular with a view to promoting consistency between the 
normative texts.’
 33
  
 
In terms of such normative instruments, the continent has developed its own codification of 
bioethics principles in the Convention for the Protection of Human Rights and Dignity of the 
Human Being with regard to the Application of Biology and Medicine: Convention on 
Human Rights and Biomedicine (the Oviedo Convention) and its associated protocols. While 
not all states are signatories of this Convention (Germany and the United Kingdom are not) it 
provides a benchmark around which European bioethics can be explored and is the only 
internationally legally binding bioethics instrument. The European Court of Human Rights 
has become increasingly engaged with bioethics. It has referred to the Oviedo Convention or 
the work of the Steering Committee on Bioethics of the Council of Europe in at least twenty 
one cases.
34
 Article 8 of the European Convention on Human Rights has proved very 
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significant in this jurisprudence, including high profile UK cases that have helped establish 
its relevance and scope in relation to bioethics issues, such as Pretty,
35
 Glass,
36
 Nicklinson
37
 
and Gard.
38
 In contrast, attempts to use Article 2 to cement either pro-life or pro-autonomy 
positions have largely been evaded by the ECtHR judges.
39
  
 
At the time of writing, the Court of Justice of the European Communities has made only 
limited reference to the Oviedo Convention, partly because the European Union is not a 
signatory. It has acknowledged the Convention’s requirement of consent before removal of 
tissue in the context of medicine, but concluded that this did not limit the patentability of 
biotechnological inventions.
40
 The Oviedo Convention’s ban on germ-line interventions was 
noted in discussions of the patentability of stem cell lines, but was not found to be material to 
the decision.
41
 The exclusion of the use of the human body and its parts for financial gain 
under the Convention has also been considered, but it was held that this did not preclude the 
application of taxation rules to the transportation of human organs and samples.
42
  
 
European Union health law is concerned primarily with the smooth running of the internal 
market not more substantive questions of bioethics,
43
 which are generally left to member 
states and subject to human rights law not that of the EU. The authors of the leading 
academic text conclude that EU health law is concerned with consumerism, human rights, the 
internal market (regulating competition, solidarity, and risk) not independently with 
bioethics. Thus, there is no convergence in European internal market law on issues such as 
abortion and euthanasia, as one would expect if bioethics was a core interest. Of course, EU 
legislation embodies ethical principles, but it is driven by more social solidarity than 
bioethics.
44  
The dominant framing in the EU regulation of technologies is neither ethics, nor 
rights, but markets.
45
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There is, here, an established European tradition of social bioethics in which the UK has 
played a significant role. The guardian is the Council of Europe rather than the European 
Union, reducing the risks that Brexit separates the UK from this tradition. A number of 
individual UK bioethicists are well regarded by colleagues and regularly called upon to 
contribute to debates. However, the express intention of travel, as indicated by the tasks 
allocation to DH-BIO, is to convergence on European bioethics principles, albeit that this 
does not necessarily imply harmonisation. 
 
The UK’s de facto national ethics committee,
46
 the Nuffield Council on Bioethics, is 
generally regarded as one of the most experienced and effective examples. Amy Guttman, 
then chair of the US Presidential Commission for the Study of Bioethical Issues has 
commented on the desirability of learining from international bodies ‘particularly, from the 
most successful ones, of which Nuffield Council is certainly up there.’
47
 its work is usually 
considered as a model in international reflections.
48
 However, a brief review of the way in 
which bioethics governance is organised in the UK will demonstrate how precarious this 
position is and suggests that proactive steps would be advisable to avoid risking a loss of 
influence and authority after Brexit. 
 
Bioethics Governance in the UK 
 
The British infrastructure for bioethics governance is fundamentally an ad hoc set of 
arrangements that are more the result of accidents of history than design. It has grown 
organically out of ‘club regulation,’
49
 and has rarely been systematically reviewed. The 
picture is complex. The UNESCO Global Ethics Observatory database identifies 41 ‘ethics 
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institutions’ in the UK, but is incomplete.
50
 It does not, for example, include the statutory 
regulators that exist in relation to particular areas of bioethics; the Human Fertilisation and 
Embryology Authority, the Human Tissue Authority, and (for England) the Health Research 
Authority. These bodies play a key role in the assurance function that the institutions of 
Bioethics Governance are expected to play, but also contribute to the establishment of norms 
and sometimes take direct responsibility for specific bioethics decisions (such as licensing the 
use of mitochondrial replacement therapies on a case specific basis.
51
 
 
The situation is both confused and confusing. Some UK bodies have legal status and powers 
(such as those just mentioned, which have a statutory basis). However, there are many 
examples of bodies that have been established informally by government; such as the Human 
Genetics Commission, the short-lived Emerging Science and Bioethics Advisory Committee, 
the Committee on the Ethics of Pandemic Influenza, and the Organ Donation Taskforce. 
Some are Non-Government Organisations that assert themselves as significant, with varying 
degrees of recognition and respect, such as the Nuffield Council on Bioethics, The Scottish 
Council on Bioethics, The Anscombe Centre, and the Falconer Commission on Assisted 
Dying.  Health professional regulators deal with some bioethics issues. Thus, the General 
Medical Council has issued important guidance on consent, confidentiality, end of life care, 
each of which has been in some way considered by and endorsed by the courts.
52
 Various 
bodies that are not specifically set up to examine bioethical matters, nevertheless issue reports 
into specific bioethical questions; these include the Royal Society,
53
 Academy of Medical 
Sciences,
54
 Wellcome Trust,
55
 Medical Research Council,
56
 and even the Royal Academy of 
Engineering.
57
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There is no apparent consistent pattern, nor rationality, to the way in which bodies are 
matched with the tasks. Some important areas of bioethics are overseen by administrative 
appointments, such as the National Data Guardian. Others are left to civil society. There is 
some democratic oversight, and important inquiries have been held by Parliamentary select 
committees; topics include reproductive technologies,
58
 abortion,
59
 genomic medicine,
60
 gene 
editing,
61
 genetically modified insects,
62
 clinical trials,
63
 mitochondrial donation,
64
 physician 
assisted suicide.
65
 In general, however, these remain discrete inquiries and bioethical matters 
are generally regarded in the UK Parliament as matters of individual conscience.
66
 It is thus 
rare for UK Governments to take the lead on issues such as abortion or euthanasia.  
 
 
The Timeliness of a Fundamental Review 
 
The last systematic government review of bioethics governance machinery was undertaken in 
1999, leading to the establishment of the Human Genetics Commission (since disbanded).
67
 It 
identified a series of main concerns that remain relevant to the current position; that the 
complexity of arrangements made it difficult for the public to understand, that the 
architecture did not properly reflect the broader ethical and environmental questions nor the 
views of potential stakeholders, and finally that they were insufficiently forward looking. The 
review also established some useful questions and implicit criteria via its consultation 
exercise. First, the importance of mapping gaps and weaknesses in the regulatory 
frameworks. Second, the need for enhanced and more consistent transparency; including 
more public consultations and open meetings. Third, the need for clarity on what is expected 
in terms of ethics contributions; with views including both the reliance on expert-ethicists and 
also on representativeness. Fourth, stakeholder views needed to be incorporated; although 
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there was no consensus on how and some concerns about building delay or creating 
mechanisms that lacked ‘tightly defined objectives’ (para 33). Fifth, flexibility was required 
and there was perceived to be a need for ‘greater foresight and greater capacity to change 
quickly’ (para 34). Finally, it was vital to ensure public confidence and ‘several respondents 
saw… the establishment of higher-level bodies as a key step in improving public confidence’ 
(para 35).  
 
Subsequent formal reviews of official bodies have been driven by either the more general 
desire to rationalize,
68
 or an ideological commitment to abolish non-government 
organisations.
69
 There are regular performance assessments of individual government arm’s 
length bodies in the form of triennial reviews. These consider whether they are still needed, 
but do not look at the wider context of bioethics governance. The future of the HFEA and 
HTA as independent bodies, and the possible merger of the two has been closely examined 
and proposed on two separate occasions.
70
 In both cases the focus was on regulatory overlap 
and efficiency rather than their effectiveness as means for facilitating public deliberation on 
challenging bioethical issues. Indeed, their role in supporting bioethics policy was ignored in 
the consultations.  
 
Commentators have long made a case for a more systematic review, especially in the form of 
a national ethics committee,
71
 They have presented their arguments to Parliamentary Select 
Committees when they have considered individual bodies or legislative areas.
72
 Thus, the 
Select Committee on Science and Technology reviewed a range of suggestions when 
examining the operation of the Human Fertilisation and Embryology Act 1990.
73
 The 
Committee noted both the variety of options and also concerns, such as those from Professor 
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Margaret Brazier, that such a body might be little more than a talking shop, hugely expensive, 
and extremely politicised.  
 
These arguments were aired in the debates around the Human Fertilisation and Embryology 
Act 2008. Those discussions probably constitute the most comprehensive publicly available 
recent consideration of what Baroness Helena Kennedy, former chair of the Human Genetics 
Commission, described as ‘the ecology of the advice given to the Government on ethics,’ 
suggesting that ‘while the ground is rather divided in this country, it is covered.’
 74
 Given the 
abolition of the HGC since that debate, she might now have a different view. A wide range of 
views was raised. Concern was expressed about the lack of statutory authority for existing 
bodies,
 75
 although it was also suggested that it would be hard for a new body to establish the 
public trust and confidence that had been achieved by the Nuffield Council and that formal 
authority was not the key issue.
 76
 Some supported the use of ad hoc committees because the 
wide range of the field precluded a single body of 6 to 8 members being able to fulfil the 
task.
77
 This was the view expressed on the part of the Government by Baroness Royall, while 
recognising the challenges:
 78
   
 
The current system means that there is a collective responsibility for bioethical 
debate, which ensures that ethical discussion is embedded in decisions across all 
committees. This distributed system of bioethical advice works well. It remains our 
view that a national human bioethics commission would not bring sufficient benefits 
in comparison. Indeed, it could lead to ethical issues being marginalised and ignored 
by committees that are responsible for guidance or policy on any number of aspects of 
medicine or the life sciences. 
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A further problem, relating to Parliamentary sovereignty, was identified when an amendment 
was debated in the House of Commons Public Bill Committee in June 2008. This proposed 
the establishment of a Parliamentary Human Fertilisation and Embryology Committee, to 
comprise fifteen MPs and fifteen members of the House of Lords.
79
 Robert Key MP set out 
what he saw as the key principle of Parliamentary sovereignty in the following terms and 
argued that ‘Both Houses of Parliament are, de facto, the national bioethics committee of this 
country. We should be jealous of that. It would not be possible to create another body, 
independent of Parliament, that would have anything like the authority that we have.
80
 Not all 
Parliamentarians saw Parliamentary sovereignty as incompatible with a national ethics 
committee. The Bishop of St Albans did not regard such a public body as ‘outsourcing’ 
ethics, but as an institution at national level to ’assist the ethical thinking that everyone in our 
country should do.
81
 Lord Brennan suggested a national bioethics commission could be used 
to promote a ‘culture of democracy’ in which bioethical reflection would no longer be limited 
to ‘regulators with ethical committees, an unaccountable private body [Nuffield] and the 
Government’.
82
 On 28 January 2008, Baroness Williams of Crosby had moved, but did not 
press to a vote, an amendment at the Report stage of the Bill that would have created National 
Human Bioethics Commission.
 83
 She saw complementary roles for legislators and a national 
commission, noting that the gaps between Parliamentary discussions were too great to 
accommodate the speed of change.  
 
Going further, Baroness Williams specifically linked the need for a national bioethics 
committee with the opportunities to influence international thinking and raised concern about 
the lack of standing in European discussions, long before Brexit.
 84 
In summarising her 
observations on the internationalisation of bioethics, Baroness Williams pointed out that 
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We are moving on to a time when it is not national legislation but European and to 
some extent international legislation that will determine the limits and constraints that 
are placed on bioethics and not least on the area of human fertilisation and 
embryology. This is exactly the area in which, as many of our leading scientists know, 
the pressures are on to weaken the principles laid down by the HFEA and others—
pressures that will grow, not decrease. A body such as a bioethics commission or, I 
agree, a parliamentary Joint Committee, would be able to bring to the Government’s 
attention the position that it takes on the Council of Ministers of the European Union 
or, more widely, on international treaty and other organisations. We are on the cusp of 
moving away from a purely national basis and do not have the proper machinery to 
deal with that. 
85
 
 
The general case for reviewing the UK’s institutions for bioethics governance based on 
fragmentation is thus enhanced by greater exposure that Brexit brings to this 
internationalisation when the UK will lose the benefit of its influence on the regional voice.  
 
To this we should add two other specific concerns whose impact is likely to be increased as a 
consequence of Brexit. First, the need to reconsider the nature of the democratisation of 
bioethics in a country that has had a taste of rule by plebiscite. A number of jurisdictions have 
seen direct democracy being deployed to determine issues through votes rather than 
committee deliberation. These include assisted dying in Oregon,
86
 stem cell research in 
California,
87
 and abortion in the Republic of Ireland.
88
 Consideration should be given to 
whether this is a tradition that might be attractive in the UK. Second, the constitutional 
transition that Brexit necessarily brings, in which the UK courts take on a stronger role,
89
 
something they were already asserting in the area of health care ethics.
90
 In the next section, 
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the shape of the challenge is explored, setting the scene for some proposals for navigating the 
post-Brexit bioethics landscape. 
 
 
Shaping the Case for Change 
 
A contemporary comprehensive review of the bioethics landscape in the UK would quickly 
identify issues of overlap and areas where responsibility is unclear. The details would be 
different, but the general picture would be essentially the same as was found in the 1999 
Review. There is considerable complexity. There is no obvious coherent principle or ethical 
framework underpinning the system. Accountability is varied, limited, and inconsistent. 
Consequently, the legitimacy of bioethics positions is often obscure. If the UK plans to 
present a strong case to be a world leader in responsible scientific innovation once it leaves 
the EU, for whom this is already a claimed strength, then it needs to bring together its 
strengths into a more coherent ‘offer’. 
 
A few examples can quickly illustrate these points, beginning with complexity. The UK is 
rightly proud of its introduction of the world’s first legislative framework for the use of 
mitochondrial replacement therapies.
91
 This avoids the precipice effect of having to classify 
techniques as either licit or illicit, without the ability to control purposes or uses. It also 
counter-acts the ‘slippery slope’ risk by retaining a case by case oversight by the licensing 
authority. However, the history of the legislation indicates the complexity of the processes 
and lack of overall oversight.
92
 The final decision-maker was Parliament, but the 
responsibility for deliberating on the bioethical issues was shared between the Human 
Fertilisation and Embryology Authority and the Nuffield Council on Bioethics, both of whom 
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held public consultations (of different types). Safety matters were reviewed under the 
auspices of the HFEA by an expert group established for the purpose. Draft regulations were 
consulted upon by the Department of Health. Two Parliamentary debates were called by 
backbenchers. A special meeting of the House of Commons Science and Technology 
Committee heard oral evidence on a single day. The net result of these activities seemed 
reasonably comprehensive, but it could hardly be described as a systematic approach and 
there was no obvious co-ordination, except perhaps through the strategic vision of the 
Wellcome Trust (arguably the poacher turning gamekeeper).
93
 
 
The continuing problem of gaps is illustrated by the limitation of the Nuffield Council of 
Bioethics, which usually sits at international bioethics meetings in the UK chair, to ‘ethical 
questions raised by recent developments in biological and medical research that concern, or 
are likely to concern, the public interest’.
94
 This has precluded discussion of long-standing 
bioethical challenges such as abortion and euthanasia and also health service rationing,
95
 
issues that are staples for most national ethics committees. Duncan Wilson has shown how 
this limitation of scope originated from a demarcation of roles to ensure the newly created 
Council on Bioethics did not tread on the toes of established institutions dealing with research 
or clinical ethics, essentially self-regulating.
96
 However, the legitimacy of this separation 
looks suspect in the contemporary context. When the Nuffield Council was established in 
1991, it might have been acceptable to leave research ethics in the hands of researchers at the 
Medical Research Council and clinical ethics in those of doctors at the BMA. It would now 
be expected that there was a more independent responsibility. The remit of the Health 
Research Authority is to take into account the ethical standards set elsewhere, not to create 
them: ‘A reference to research that is ethical is a reference to research that conforms to 
generally accepted ethical standards.’
97
 There is a gap in the structures; no one is accountbale 
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for developing those generally accepted standards. Similarly, there is a legal process for 
research ethics committees to be legally recognised by the Health Research Authority under 
the Care Act 2014. However, there remains no requirement for clinical ethics committees to 
be established in NHS hospitals, despite Article 19 of the UNESCO Declaration on Bioethics 
(2015) referring to the expectation of ‘independent, multidisciplinary and pluralist ethics 
committees... to … provide advice on ethical issues in clinical settings’ and long-standing 
interest in their value.
98
 Those clinical ethics committees that exist are supported by an 
informal network, based within Warwick Medical School.
99
 The governance framework is 
thus far from comprehensive. 
  
There are other challenges of legitimacy too. The reliance on a non-government body to play 
the role of a national ethics committee may be consistent with traditional British political 
pragmatism, but it is problematic when judged in relation to democratic accountability. There 
are many different ways to integrate bioethics into constitutional government. National Ethics 
Committees can be part of the executive, constituted to provide advice to the Government (as 
with most of the recent US national Bioethics Commissions, although some were established 
by Congress).
100
 They can be established within the legislative process in order to ensure 
parliaments are properly informed of bioethical issues when they arise for consideration. The 
French Comite Consultatif National d’Ethique currently has this function.
101
 In other systems, 
bioethics deliberation may be established as a representative form of democracy (as in 
Belgium, where people from the main communities need to be appointed to the national 
Advisory Committee on Bioethics).
102
 The political authority of bodies in each of these 
approaches can be explained in terms of constitutional law. In the UK, however the position 
of the Nuffield Council is based on tacit acceptance and the absence of a formally recognised 
national ethics committee.
 103
  Its reputation has been established over time,
104
 by its virtues 
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and practices,
 105
 but these provide only limited democratic legitimacy.
 106
 Post-Brexit, the 
need for constitutional recognition is likely to become more important as the UK seeks to 
establish that it conforms to international expectations in relation to bioethics. The 
informality of bioethics oversight, consequent apparent lack of compliance with the 
expectations of the UNESCO Declaration and its failure to endorse the Oviedo convention 
may undermine the UK’s claim to be a strong regulator of ethically problematic scientific 
advance. 
 
The constitutional authority over bioethical issues is currently in a state of flux. The UK 
judiciary are testing the demarcation between issues of human rights, with which bioethics 
governance structures must comply and matters of judgments that fall to Parliament or the 
institutions that it creates or tacitly recognises. We have moved a great distance from the 
view expressed by the House of Lords in the Pretty case that Article 8 ECHR rights were not 
engaged by limitations on assisted suicide, a view that was premised on bioethics issues 
being outside of the scope of human rights law because they were more appropriate for 
democratic deliberation.
107
 The European Court of Human Rights took a different view, and 
held that Article 8 was engaged, but that the limitations were justified by the need to protect 
the rights and freedoms of others under Article 8(2).
108
 Thus, bioethical issues that engage 
human rights are suspect to judicial supervision, albeit with a significant margin of 
appreciation.
109
 
 
The demarcation of responsibilities between judiciary, executive and legislature is an 
important aspect of the constitutional legitimacy of a more explicit governance framework for 
bioethics issues. In the Nicklinson case, the majority of the Supreme Court asserted the right 
to judge the proportionality of legislative interference with autonomy of those who are 
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terminally ill.
110
 The analysis in Nicklinson also suggests that the buffer that has been created 
in the jurisprudence of the European Court of Human Rights, under the concept of the margin 
of appreciation, does not apply to the domestic context. Consequently, the assessment of 
proportionality is asserted to lie with the courts rather than Parliament, applying the tests 
from the Aguilar Quila case.
111
 Some recent case law suggests that the judiciary may be wary 
of pushing the logic of Nicklinson too far and the Court of Appeal in Conway has reiterated a 
fairly traditional account of why judges should generally defer to Parliament on matters of 
‘moral value-judgment’ as it is ‘the conscience of the nation’.
112
 However, the Supreme 
Court was clear that abortion law in Northern Ireland was incompatible with the Convention, 
even though it held that the NI Human Rights Commission lacked standing to bring the case 
placed before it.
113
 The need for clarification on the proper scope of democratic deliberation 
in bioethics is apparent. 
 
 
The challenge of explaining who has legitimate authority in UK bioethics deliberations is 
exacerbated by the longstanding resistance to principle in this area of law, something that has 
contributed to the ambiguities discussed earlier over how ‘European’ UK approaches have 
been. This resistance to formalising bioethics can be seen in the courts persistent use of 
professional standards to facilitate an arms-length approach to oversight.
114
 The UK has no 
fundamental law on bioethics. It has not signed the Oviedo Convention. Its institutions tend 
to avoid seeking consistency through the articulation and application of principles in favour 
of a case by case approach. There are some exceptions, such as the Human Genetics 
Commission’s discussion of genetic solidarity and altruism in Inside Information, which were 
then used as a reference point for its future work.
115
 More common, however, is the approach 
of the Nuffield Council on Bioethics, which has avoided a principle-based approach in favour 
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of a procedural sense of legitimacy based on the inclusiveness of its listening processes, and 
the rigorous quality of the tests of rationality it applies to the arguments.
116
 It seeks, through 
open calls to evidence, the publication of working papers, and consultative processes, to 
ensure that no voices are excluded but that they are engaged with through a form of public 
reason.
117
 It has articulated an approach based on the quality of public discourse.
118
 The long-
standing British approach, exemplified by the Warnock Committee’s proposal of the 14 day 
limit on embryo research, has tended to assume that public policy should be driven by 
acceptability as much as principle.
119
  
 
On this approach, public bioethics proceeds as much by jurisdictional demarcation than 
resolution. I have argued elsewhere, that the prohibition on embryo research after the 
emergence of the primitive streak (deemed to appear not later than the end of the fourteenth 
day) is better understood as a jurisdictional device aimed to ensure that any change was 
reserved to Parliament than as a statement about the moral status of the biological entity.
120
 
This points again to the importance of understanding the constitutional structure of British 
bioethics governance and the basis of its claims to legitimacy.  
 
The case for undertaking a review of the institutions of UK bioethics governance is thus 
based on a number of strands that have been explored in this section. First, the need to 
simplify the complexity of the ecology of oversight that has evolved rather than been 
designed. Second, the importance of plugging gaps to ensure that the system is 
comprehensive. Third, to clarify and resolve the constitutional issues that will demonstrate 
the legitimacy of decision-making. A review should also result in more streamlined 
procedures and provide substance to the claim that the UK can be a world leader in regulation 
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and ethics that the Minister made in July 2018. In that sense, it would assist the UK in setting 
out its stall for promoting responsible scientific innovation post-Brexit  
 
The need for review must be put in perspective, however. Despite the issues just explored, the 
reputation of UK in the international bioethics community is currently very high; the concern 
is not to establish it but to retain it. In particular, whether Brexit might diminish it. The 
Nuffield Council on Bioethics plays a leading role in the international activities of national 
bioethics committees (even though it has no official status), with the Director frequently 
invited to be part of organising committees for the WHO Global Summit of National 
Bioethics Committees and of the European NEC Form. The UK has a number of leading 
bioethics centres and, largely thanks to the Wellcome Trust, there is significant investment in 
bioethics research. The UK hosts two of the leading journals in the area, Bioethics and the 
Journal of Medical Ethics. The question is how to maintain this reputation. Brexit may be 
marginal to this matter, but it has raised questions about the UK’s commitment to continuing 
engagement to regional institutions that it would be advisable to address. 
 
Next Steps 
 
In summary, the challenge of Brexit to bioethics lies in establishing a more coherent ‘brand’ 
for the currently disparate governance institutions. We need to do this in order to demonstrate 
that the UK is a safe and attractive place to carry out responsible science even though we 
have distanced ourselves from the European project to this effect.
121
 We also need to ensure 
that we maintain our presence in what Pete Mills, Assistant Director of the Nuffield Council 
of Bioethics has described as the ‘debating chambers’ in which global bioethics is pursued 
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and from which we may become ‘distanced’ if we do not take proactive steps.
122
 To achieve 
this we should address three challenges; those of co-ordination, influence, and principle. 
 
First, we need to reshape our ad hoc, distributed, network of bioethics bodies into a co-
ordinated network. It would be possible to introduce a new national bioethics commission, or 
a standing Parliamentary Committee, as discussed above. However, this would fail to build 
on the reputations of our current bioethics organisations. A more successful model could be 
built from the experience of the Professional Standards Authority,
123
 which was introduced 
(initially as the Council for the Regulation of Health Care Professionals) to oversee the work 
of the separate regulators for professional groups (e.g. medicine, nursing and midwifery, 
dentists, pharmacists etc) following the Bristol Royal Infirmary Inquiry.
124
 Under the NHS 
Reform and Health Care Professions Act 2002, the new council was charged with promoting 
good practice, formulating principles relating to good professional self-regulation and 
promoting co-operation.
125
  
 
Rather than supplanting established regulators, it sought to harness their expertise and 
encourage a levelling up of performance. Something similar was suggested to the 1999 
review of bioethics advisory machinery: that ‘better co-ordination could be achieved through 
the establishment of a standing body comprising the Chairs of existing committees’.
126
 There 
was also a call for ‘an over-arching ethics committee (perhaps comprising representatives of 
all the key advisory/regulatory committees)’.
127
  The creation of a Council of Bioethics 
Advisory Bodies would enable the UK to speak with a single voice when necessary, but 
without compromising the different functions of the existing institutions. Devolution will, no 
doubt, provide some significant challenges, as bioethics is an area where there are important 
variations. However, it will be hard for the UK to explain why its bioethics is well-governed 
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if it cannot co-ordinate oversight. If it cannot explain this, then its reputation for progressive 
but regulated science will be at risk. 
 
Linked with this, is the importance of a strategic approach to ‘soft power’ in bioethics. Pete 
Mills raised concerns that membership of key groups at European level, such as the NEC 
Forum and European Group on Ethics in Science and New Technologies, might be at risk 
(although at present both are open to non-EU members).
 128
 The UK does not currently have a 
member on the UNESCO International Bioethics Committee, but perhaps needs to seek to 
secure a place if it is to maintain influence. The last UK member of the IBC was Professor 
Sheila Maclean, whose term ended with the 2012-3 session. Brexit will mean loss of 
influence at the International Council for Harmonisation, which sets guidelines for 
pharmaceutical development, and which is dominated by the three key regulated markets of 
Europe, Japan and the USA. It is a non-profit association, but its decisions are crucial for 
successful drug development which is now a global enterprise and in which the UK will be 
concerned not to lose ground.
129
 After Brexit, the UK will not necessarily have a place at the 
table. Similar issues arise in relation to the work of the World Health Organisation. The UK 
does not host a WHO Collaborating Centre for Bioethics. A strategic approach to securing 
influence may prove essential if we want UK bioethics to thrive after Brexit. 
 
Finally, there is the issue of the UK’s resistance to principle. It might be that the judges will 
develop through the Human Rights Act an elaboration of bioethics that will serve to underpin 
the UK’s approach. It might also be the case that bringing together the bioethics bodies in the 
manner that has been suggested will lead to the articulation of common principles. However, 
the most symbolic act that the UK could take to show that it was part of the international 
bioethics community would be to sign the Oviedo Convention. This is not necessarily 
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straightforward. The Convention is showing its age; some of the terminology is difficult to 
interpret in the light of current science, and the subtleties of the genealogy of articles has not 
always been kept in mind.
130
 Following the 20
th
 Anniversary Conference in 2017,
 131
  there is 
to be a ‘Strategic Action Plan aimed at defining the main axes and objectives of the work of 
DH-BIO in the next few years, where appropriate in cooperation with other committee and/or 
intergovernmental organisations, to address key human rights challenges raised by 
developments in the biomedical field.’
132
 It would be an opportune time for the UK to show 
its commitment to the European tradition of bioethics by signing the Convention and for it to 
play a full part it the promised exploration of its implications. That would show that, despite 
Brexit, we have not rejected participation in the global common purpose in bioethics and that 
we remain committed to the liberal democratic values of Europe; exactly as Prime Minister 
May stated in her letter of 29 March 2017, triggering Article 50.  
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